Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases

INTRODUCTION: Dysregulated complement activation is likely the primary driver of disease in C3 glomerulopathy (C3G) and contributes to other complement-mediated diseases, including immunoglobulin A nephropathy (IgAN), lupus nephritis (LN), and primary membranous nephropathy (PMN). No complement inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dixon, Bradley P., Greenbaum, Larry A., Huang, Liwei, Rajan, Sandeep, Ke, Chunlei, Zhang, Yiwei, Li, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658235/
https://www.ncbi.nlm.nih.gov/pubmed/38025230
http://dx.doi.org/10.1016/j.ekir.2023.08.033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658235/
https://www.ncbi.nlm.nih.gov/pubmed/38025230
http://dx.doi.org/10.1016/j.ekir.2023.08.033

Ejemplares similares